Developing a genetic signature to predict drug response in ovarian cancer

There is a lack of personalized treatment options for women with recurrent platinum-resistant ovarian cancer. Outside of bevacizumab and a group of poly ADP-ribose polymerase inhibitors, few options are available to women that relapse. We propose that efficacious drug combinations can be determined...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyter, Stephen, Hirst, Jeff, Pathak, Harsh, Pessetto, Ziyan Y., Koestler, Devin C., Raghavan, Rama, Pei, Dong, Godwin, Andrew K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871081/
https://www.ncbi.nlm.nih.gov/pubmed/29599910
http://dx.doi.org/10.18632/oncotarget.23663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871081/
https://www.ncbi.nlm.nih.gov/pubmed/29599910
http://dx.doi.org/10.18632/oncotarget.23663

Ejemplares similares